Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 762.32 Million CNY | -12.38% |
| 2022 | 870.02 Million CNY | 21.74% |
| 2021 | 714.64 Million CNY | -62.7% |
| 2020 | 1.91 Billion CNY | 3.71% |
| 2019 | 1.84 Billion CNY | 30.42% |
| 2018 | 1.41 Billion CNY | 39.24% |
| 2017 | 1.01 Billion CNY | 25.63% |
| 2016 | 809.85 Million CNY | -42.68% |
| 2015 | 1.41 Billion CNY | 15.15% |
| 2014 | 1.22 Billion CNY | 16.14% |
| 2013 | 1.05 Billion CNY | 48.12% |
| 2012 | 713.21 Million CNY | 69.48% |
| 2011 | 420.81 Million CNY | 30.52% |
| 2010 | 322.41 Million CNY | 150.82% |
| 2009 | 128.54 Million CNY | -1.7% |
| 2008 | 130.76 Million CNY | 22.47% |
| 2007 | 106.77 Million CNY | 75.86% |
| 2006 | 60.71 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 854.29 Million CNY | 12.06% |
| 2024 Q2 | 779.12 Million CNY | -8.8% |
| 2024 Q3 | 929.26 Million CNY | 19.27% |
| 2023 Q1 | 902.18 Million CNY | 3.7% |
| 2023 FY | 762.32 Million CNY | -12.38% |
| 2023 Q4 | 762.32 Million CNY | -3.24% |
| 2023 Q3 | 787.82 Million CNY | -3.51% |
| 2023 Q2 | 816.48 Million CNY | -9.5% |
| 2022 FY | 870.02 Million CNY | 21.74% |
| 2022 Q1 | 825.86 Million CNY | 15.56% |
| 2022 Q4 | 870.02 Million CNY | 4.4% |
| 2022 Q2 | 846.54 Million CNY | 2.5% |
| 2022 Q3 | 833.34 Million CNY | -1.56% |
| 2021 Q3 | 656.39 Million CNY | -14.35% |
| 2021 Q4 | 714.64 Million CNY | 8.87% |
| 2021 Q2 | 766.35 Million CNY | -41.75% |
| 2021 FY | 714.64 Million CNY | -62.7% |
| 2021 Q1 | 1.31 Billion CNY | -31.34% |
| 2020 Q1 | 1.77 Billion CNY | -3.93% |
| 2020 FY | 1.91 Billion CNY | 3.71% |
| 2020 Q2 | 1.88 Billion CNY | 6.39% |
| 2020 Q3 | 2 Billion CNY | 6.12% |
| 2020 Q4 | 1.91 Billion CNY | -4.38% |
| 2019 Q1 | 1.74 Billion CNY | 23.29% |
| 2019 FY | 1.84 Billion CNY | 30.42% |
| 2019 Q2 | 1.81 Billion CNY | 3.68% |
| 2019 Q4 | 1.84 Billion CNY | 3.3% |
| 2019 Q3 | 1.78 Billion CNY | -1.23% |
| 2018 Q4 | 1.41 Billion CNY | 2.41% |
| 2018 FY | 1.41 Billion CNY | 39.24% |
| 2018 Q3 | 1.38 Billion CNY | 4.81% |
| 2018 Q2 | 1.31 Billion CNY | 8.64% |
| 2018 Q1 | 1.21 Billion CNY | 19.41% |
| 2017 Q2 | 969.96 Million CNY | 4.84% |
| 2017 Q1 | 925.21 Million CNY | 14.25% |
| 2017 Q3 | 1.1 Billion CNY | 13.44% |
| 2017 Q4 | 1.01 Billion CNY | -7.53% |
| 2017 FY | 1.01 Billion CNY | 25.63% |
| 2016 Q4 | 809.85 Million CNY | -6.89% |
| 2016 Q3 | 869.75 Million CNY | -0.65% |
| 2016 Q2 | 875.45 Million CNY | -1.14% |
| 2016 Q1 | 885.57 Million CNY | -37.32% |
| 2016 FY | 809.85 Million CNY | -42.68% |
| 2015 Q2 | 1.54 Billion CNY | 6.0% |
| 2015 Q4 | 1.41 Billion CNY | -3.57% |
| 2015 FY | 1.41 Billion CNY | 15.15% |
| 2015 Q3 | 1.46 Billion CNY | -5.2% |
| 2015 Q1 | 1.45 Billion CNY | 18.83% |
| 2014 Q2 | 1.26 Billion CNY | 10.3% |
| 2014 FY | 1.22 Billion CNY | 16.14% |
| 2014 Q1 | 1.14 Billion CNY | 8.6% |
| 2014 Q3 | 1.18 Billion CNY | -6.26% |
| 2014 Q4 | 1.22 Billion CNY | 3.44% |
| 2013 Q1 | 883.35 Million CNY | 23.86% |
| 2013 Q2 | 974.97 Million CNY | 10.37% |
| 2013 FY | 1.05 Billion CNY | 48.12% |
| 2013 Q3 | 1.1 Billion CNY | 13.05% |
| 2013 Q4 | 1.05 Billion CNY | -4.16% |
| 2012 Q3 | 714.98 Million CNY | 4.24% |
| 2012 Q4 | 713.21 Million CNY | -0.25% |
| 2012 Q2 | 685.89 Million CNY | 57.96% |
| 2012 FY | 713.21 Million CNY | 69.48% |
| 2012 Q1 | 434.21 Million CNY | 3.18% |
| 2011 Q2 | 406.35 Million CNY | 8.96% |
| 2011 FY | 420.81 Million CNY | 30.52% |
| 2011 Q4 | 420.81 Million CNY | 4.93% |
| 2011 Q3 | 401.05 Million CNY | -1.3% |
| 2011 Q1 | 372.95 Million CNY | 15.67% |
| 2010 Q1 | 137.94 Million CNY | 7.31% |
| 2010 Q4 | 322.41 Million CNY | 78.4% |
| 2010 FY | 322.41 Million CNY | 150.82% |
| 2010 Q3 | 180.72 Million CNY | 7.15% |
| 2010 Q2 | 168.67 Million CNY | 22.27% |
| 2009 Q2 | 132.66 Million CNY | 0.0% |
| 2009 FY | 128.54 Million CNY | -1.7% |
| 2009 Q4 | 128.54 Million CNY | -19.6% |
| 2009 Q3 | 159.87 Million CNY | 20.51% |
| 2008 Q4 | 130.76 Million CNY | 0.0% |
| 2008 FY | 130.76 Million CNY | 22.47% |
| 2007 FY | 106.77 Million CNY | 75.86% |
| 2006 FY | 60.71 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 9.12 Billion CNY | 91.648% |
| Zhejiang Zhenyuan Share Co., Ltd. | 974.86 Million CNY | 21.802% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.21 Billion CNY | 37.207% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 1.63 Billion CNY | 53.434% |
| Yifan Pharmaceutical Co., Ltd. | 3.14 Billion CNY | 75.76% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 84.57 Million CNY | -801.319% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 13.22 Billion CNY | 94.234% |
| Boai NKY Medical Holdings Ltd. | 499.66 Million CNY | -52.568% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 258.46 Million CNY | -194.947% |